ADT1756-Human Anti-CD3xCD20 Bispecific Antibody
- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1756 |
Product Name |
ADT1756-Human Anti-CD3xCD20 Bispecific Antibody |
Isotype |
Human IgG1-kappa/lambdawith domain crossover, trivalent |
Clonity |
Monoclonal |
|
Alternate Names Human Anti-CD3 mAb, Anti-CD3 Monoclonal Antibody, CD3 recombinant antibody, Anti-CD3 Bispecific Antibody, Human Anti-CD20 mAb, CD20 recombinant antibody, Anti-CD20 Monoclonal Antibody, Anti-CD20 Bispecific Antibody |
|
Official Symbol |
CD3xCD20 |
Target 1 |
CD3 |
Gene ID 1 |
916 |
Target 2 |
CD20 |
Gene 2 |
931 |
Species |
Human |
Drug Name |
Glofitamab |
CAS Number |
2229047-91-8 |
Product Description |
Glofitamab is a bispecific monoclonal antibody directed against CD20 and CD3 which is used for the treatment of relapsed or refractory diffuse large B-cell lymphoma. |
Mechanism of Action |
Glofitamab is a bispecific monoclonal antibody targeted towards CD20 surface antigens - found on B-cells - and CD3 protein complexes found on the surface of T-cells.It binds bivalently to CD20 and monovalently to CD3, thereby creating an immunological synapse that serves to recruit T-cells to CD20-expressing B-cells. This simultaneous binding allows for potent T-cell activation and proliferation which ultimately results in the lysis of the target B-cells. |
Metabolism |
The metabolism of glofitamab has not been directly studied. As with other therapeutic antibodies, it is likely metabolized primarily via catabolism to smaller peptides and amino acids. |
Molecular Weight |
194 KDa |
Endotoxin |
<1EU/mg. Determined by the LAL method. |
Sterility |
0.2 μM filtered. |
Expression Host |
CHO Cells |
Size |
1mg,5mg,50mg,100mg |
Research Area |
Cancer |
Application |
FuncS |
Purity |
>90% |
Concentration |
Batch dependent |
Buffer |
Supplied in PBS, pH 7.4,Contains no stabilizers or preservatives |
Recommended Dilution Buffer |
ABDB-1002 or PBS, pH 7.4, Contains no stabilizers or preservatives. |
Storage |
2 weeks, 2-8℃ under sterile conditions after reconstitution. Avoid repeated freeze-thaw. -80°C for one-year storage. |
Shipping Condition |
Shipped on ice packs. |
Protocol Information |
Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose-response or titration experiment. |
Note |
For Research Use Only! |
|
Reference 1. Wang C, Liu Y: Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting. J Hematol Oncol. 2023 Mar 10;16(1):20. doi: 10.1186/s13045-023-01420-w.
2. Gonzalez Barca E: Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era. Front Immunol. 2022 Jul 19;13:909008. doi: 10.3389/fimmu.2022.909008. eCollection 2022.
|
FAQ
-
+ -
What are the main therapeutic applications of CD3-targeting antibodies?
CD3-targeting antibodies are widely used in hematologic malignancies, such as acute lymphoblastic leukemia (ALL) and multiple myeloma. Bispecific T-cell engagers (BiTEs) and monoclonal antibodies (mAbs) targeting CD3 are also being developed for solid tumors.
-
+ -
How can I obtain Request Quote of the reagent that I received?
Please contact us via email info@alphalifetech.com for detailed information about the product.
-
+ -
What are the challenges in targeting CD20 for therapy?
Resistance to anti-CD20 therapy can develop due to antigen loss, mutations, or immune evasion. Next-generation CD20 antibodies and combination therapies aim to overcome these challenges by enhancing the efficacy and durability of response. -
+ -
How are bispecific antibodies evaluated in preclinical studies?
Assays include binding affinity (SPR/BLI), cell-based cytotoxicity, pharmacokinetics, and toxicity profiling in animal models.






